Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma

Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma

ObjectiveTo evaluate the efficacy and safety of Tislelizumab combined with Axitinib in the treatment of intermediate-high risk metastatic clear-cell renal cell carcinoma (ccRCC).MethodsFrom September 2021 to June 2023, a total of 20 untreated patients with intermediate-high risk metastatic advanced...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Cui, Pengyong Xu, Changying Guo, Yong Guan, Kejia Zhu, Sentai Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
clear-cell renal cell carcinoma
tislelizumab
axitinib
first-line treatment
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1618898/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items